Hospital Ac Camargo

São Paulo 01509-900

2 studies enrolling now · 7 studies all time

What they study most

Breast Cancer, Giant Cell Glioblastoma, Glioblastoma, Glioblastoma With Oligodendroglial Component, Gliosarcoma, Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen, Mantle Cell Lymphoma, Non-small Cell Lung Cancer (NSCLC), Septic Shock, Small Cell Glioblastoma, Vasodilatory Shock

Studies at this site

• Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) — Recruiting now
• Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen — Recruiting now
• Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) — Running, not enrolling
• Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) — Running, not enrolling
• Heparin Anticoagulation in Septic Shock — Stopped early
• Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma — Completed
• Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma — Completed